Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmacovigilance

UK regulator appeals to patients with animation about reporting drug side effects

Mick Foy, group manager for the MHRA’s vigilance and risk management of medicines division

Source: The Medicines and Healthcare products Regulatory Agency

Mick Foy says the campaign “will help the public, patients and healthcare professionals report potential side effects and have confidence that their reports are making a difference”

A short animation about the value of reporting drug side effects is being used as part of a social media campaign by the UK’s drug safety watchdog.

The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medicines and medical devices in the UK, hopes the animation, available on YouTube, will encourage patients to report side effects directly or to inform health professionals about the side effects they are experiencing so they can be officially recorded.

Mick Foy, group manager for the MHRA’s vigilance and risk management of medicines division, says: “Our campaign will help the public, patients and healthcare professionals report potential side effects and have confidence that their reports are making a difference.”

He says any suspected side effects can be reported easily and quickly through the MHRA’s Yellow Card scheme, either online or via a mobile app.

The MHRA campaign, which began on 7 November 2016 and will run until 11 November 2016, is part of the Europe-wide Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) joint action project. The project is being supported by 22 EU member states.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201926

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Mick Foy, group manager for the MHRA’s vigilance and risk management of medicines division

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.